Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NordicTrip
NCT04335669Phase 3Active, not recruiting
- Sponsor
- Skåne University Hospital
- Start
- Dec 2019
- Primary completion
- Sep 2035
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of capecitabine in triple-negative breast cancer (TNBC), sponsored by Skåne University Hospital. Started Dec 2019; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04335669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335669.